作为肺癌精准治疗的标杆领域，表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）的治疗格局在过去十年间发生了革命性变化。从第一代 EGFR 酪氨酸激酶抑制剂（TKI） 的初步探索，到第三代 TKI 成为标准治疗，再到联合治疗、耐药后精准施策的多元化布局，每一步进展都深刻改变了临床实践。本文基于近期发表于 Frontiers ...

脑转移已成为非小细胞肺癌（NSCLC）患者治疗全程管理中的重大挑战，在携带驱动基因突变（如 EGFR 突变）的患者中尤为突出。传统治疗（如放射治疗和外科手术）的临床获益有限，且常伴随认知功能障碍和生活质量下降[1]。随着 EGFR ...

Accelerated repopulation is a main reason for locoregional failure after fractionated radiotherapy for head and neck squamous cell carcinoma (HNSCC). Epidermal growth factor receptor (EGFR) is a key ...

“We postulate that these observations may provide novel opportunities for therapeutic interventions for EGFR driven cancers.” “We postulate that BUB1 helps in the formation and stabilization of EGFR ...

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial We derived disease progression and therapy ...

The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...